Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) Equity Income (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Equity Income for 6 consecutive years, with $247.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Income rose 22840.83% to $247.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $255.1 million, a 1910.44% increase, with the full-year FY2025 number at $255.1 million, up 1910.44% from a year prior.
  • Equity Income was $247.9 million for Q4 2025 at Beam Therapeutics, up from $4.9 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $247.9 million in Q4 2025 to a low of -$13.7 million in Q3 2022.
  • A 5-year average of $13.0 million and a median of -$2.1 million in 2024 define the central range for Equity Income.
  • Peak YoY movement for Equity Income: plummeted 839.65% in 2022, then surged 22840.83% in 2025.
  • Beam Therapeutics' Equity Income stood at -$4.3 million in 2021, then surged by 1170.01% to $45.7 million in 2022, then plummeted by 101.58% to -$722000.0 in 2023, then crashed by 50.97% to -$1.1 million in 2024, then soared by 22840.83% to $247.9 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Equity Income are $247.9 million (Q4 2025), $4.9 million (Q3 2025), and $4.4 million (Q2 2025).